Haisco(SZ:002653) Di Yi Cai Jing·2026-01-09 15:54Core Insights - The article highlights the significant growth in China's innovative drug licensing transactions, projecting a total value exceeding $130 billion by 2025 [1] - In early 2026, a new wave of licensing deals is beginning, indicating ongoing momentum in the sector [1] Company Summary - On January 9, 2026, the company Haisco (002653.SZ) announced a licensing agreement with the U.S. firm AirNexis, granting exclusive rights for the global development, production, and commercialization of its innovative drug HSK39004, excluding Greater China [1] - The licensing transaction is structured through a Newco model, where a new company is formed to manage the licensed pipeline, allowing the pharmaceutical company to retain equity and receive cash [1]